Policy‐Evidence Misalignment in Commercial Payer Coverage Criteria for Knee Osteochondral Allograft Transplantation
- 1Rush University Medical Center Chicago Illinois U.S.A.
- 2Rush University Medical College Chicago Illinois U.S.A.
Abstract
Purpose
To evaluate how major United States commercial insurers justify medical-necessity criteria for knee osteochondral allograft (OCA) transplantation, characterize the level of evidence (LOE) cited within their policies, and assess whether coverage criteria are supported by the cited literature.Methods
Four major national commercial insurers with publicly available knee OCA policies were identified, and the most recent policy versions were retrieved. Medical-necessity criteria were extracted, and all cited references applicable to knee OCA were screened, assigned an LOE and publication date, and coded for whether they supported each policy criterion. Coverage stance by lesion site was summarized. Publicly available revision histories were reviewed to compare administrative revision and evidence-refresh cadence. A deidentified institutional dataset of current procedural terminology 27415 authorization requests was reviewed to contextualize findings in real-world coverage outcomes.Results
Across the 4 insurers, 40 applicable references were cited: Level V n = 7 (17.5%), Level IV n = 30 (75.0%), and Level III n = 3 (7.5%); Level I and II were 0. One insurer provided no OCA-specific coverage criteria and instead deferred determinations to proprietary criteria not publicly available. Among the remaining 3 insurers, coverage was most permissive for unipolar femoral condyle lesions. Patellar lesions were explicitly excluded by 1 insurer, whereas bipolar and tibial plateau lesions were each excluded by 2 insurers. Among payers with assessable revision histories, administrative revisions occurred more frequently than documented evidence-refresh events. In an institutional dataset of 34 current procedural terminology 27415 requests, 7 (20.6%) were initially denied; all cases with documented outcomes were ultimately approved after escalation.Conclusions
Commercial payer knee OCA policies are largely based on older, low-level evidence, and cited literature seldom supports key medical-necessity criteria.Clinical relevance
Identifying discrepancies between insurance coverage and clinical evidence may help clinicians advocate more effectively during preauthorization and appeal processes, reduce delays in care, and inform payers' efforts to align coverage criteria with modern outcome data.
Related
- Adverse Graft Remodeling Reflects Dynamic Allograft Stress and Predicts Adverse Outcomes After Heart Transplantation
- Transosseous Equivalent Meniscus Allograft Transplantation Using an All-Suture-Based Anchor Technique.
- Impact of Aspirin Use on Mortality and Cardiac Allograft Vasculopathy After Heart Transplantation: A Systematic Review and Meta-analysis.
- Possible baseline lung allograft dysfunction within the first year defines a high-risk and potentially reversible state after lung transplantation
- Functional activity of anti-endothelin type A receptor antibodies as a predictive tool of allograft injury in pediatric kidney transplantation
BibTeX
@article{amin2026policyevidence,
title = {{Policy‐Evidence Misalignment in Commercial Payer Coverage Criteria for Knee Osteochondral Allograft Transplantation}},
author = {Jay S Amin and Divesh Sachdev and Kofi K Acheampong and Camden Richter and Nicholas Lemme and Brian J Cole and Adam B Yanke},
journal = {Arthroscopy, sports medicine, and rehabilitation},
year = {2026},
month = oct,
doi = {10.1002/ars2.70094},
url = {https://europepmc.org/article/PMC/PMC13718874},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Policy‐Evidence Misalignment in Commercial Payer Coverage Criteria for Knee Osteochondral Allograft Transplantation
AU - Jay S Amin
AU - Divesh Sachdev
AU - Kofi K Acheampong
AU - Camden Richter
AU - Nicholas Lemme
AU - Brian J Cole
AU - Adam B Yanke
PY - 2026
DA - 2026/10/29
JO - Arthroscopy, sports medicine, and rehabilitation
DO - 10.1002/ars2.70094
UR - https://europepmc.org/article/PMC/PMC13718874
AB - Purpose To evaluate how major United States commercial insurers justify medical-necessity criteria for knee osteochondral allograft (OCA) transplantation, characterize the level of evidence (LOE) cited within their policies, and assess whether coverage criteria are supported by the cited literature.Methods Four major national commercial insurers with publicly available knee OCA policies were identified, and the most recent policy versions were retrieved. Medical-necessity criteria were extracted, and all cited references applicable to knee OCA were screened, assigned an LOE and publication date, and coded for whether they supported each policy criterion. Coverage stance by lesion site was summarized. Publicly available revision histories were reviewed to compare administrative revision and evidence-refresh cadence. A deidentified institutional dataset of current procedural terminology 27415 authorization requests was reviewed to contextualize findings in real-world coverage outcomes.Results Across the 4 insurers, 40 applicable references were cited: Level V n = 7 (17.5%), Level IV n = 30 (75.0%), and Level III n = 3 (7.5%); Level I and II were 0. One insurer provided no OCA-specific coverage criteria and instead deferred determinations to proprietary criteria not publicly available. Among the remaining 3 insurers, coverage was most permissive for unipolar femoral condyle lesions. Patellar lesions were explicitly excluded by 1 insurer, whereas bipolar and tibial plateau lesions were each excluded by 2 insurers. Among payers with assessable revision histories, administrative revisions occurred more frequently than documented evidence-refresh events. In an institutional dataset of 34 current procedural terminology 27415 requests, 7 (20.6%) were initially denied; all cases with documented outcomes were ultimately approved after escalation.Conclusions Commercial payer knee OCA policies are largely based on older, low-level evidence, and cited literature seldom supports key medical-necessity criteria.Clinical relevance Identifying discrepancies between insurance coverage and clinical evidence may help clinicians advocate more effectively during preauthorization and appeal processes, reduce delays in care, and inform payers' efforts to align coverage criteria with modern outcome data.
SN - 2666-061X
ER -